Medical marijuana has been legal in California for over 20 years. Now, the state is joining 5 other U.S. states to introduce the sale of recreational marijuana. Kris Krane, President and Co-Founder of 4Front Ventures, an investment and management firm in the cannabis industry, was with us to discuss the implications of the new law. Krane says legalization of recreational marijuana will spark a domino-effect in the rest of the country. Colorado, Washington, Oregon, Alaska and Nevada beat the Golden State to it, but Krane says California's decision will be the most impactful due to the state's size and influence on policy. Krane believes an open and legal market will make it increasingly untenable for the rest of the country to maintain prohibition. Despite leniency on the state level, Krane still sees a hurdle on the federal level. This obstacle will make it challenging for cannabis companies to list on the major stock exchanges in the U.S., he adds. As a result, he thinks the most significant public market movement will continue to take place in Canada, where companies can access the Toronto Stock exchange and other major Canadian exchanges.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More